Management to Host Investor Conference Call Tomorrow, Friday, January 27 at 8:45 a.m. ET
SAN DIEGO, CA, USA I January 26, 2012 I Lpath, Inc. (OTCBB: LPTN), the industry leader in lipidomics-based antibody therapeutics, has temporarily suspended dosing patients in its PEDigree and Nexus trials. In these trials, iSONEP(TM) is being tested as a treatment for wet AMD (Nexus) and a related complication called Pigmented Epithelial Detachment (PEDigree).
The company has taken this action because it learned from the FDA that the company’s fill/finish contractor, Formatech, Inc., was not in compliance with FDA’s current Good Manufacturing Practice (cGMP) requirements during the period that the iSONEP clinical vials were filled. Accordingly, even though Lpath believes it has taken appropriate steps to oversee Formatech’s manufacturing in order to ensure product quality, it has suspended dosing as a precaution to ensure the continued safety of all patients in its clinical trials.
iSONEP was well tolerated by all patients in the Phase 1 trial and by all patients thus far in the PEDigree and Nexus trials. The company has received no claims raising safety concerns regarding iSONEP.
Lpath has initiated the process to manufacture additional drug substance and has identified an alternate fill/finish contractor. Lpath plans to resume dosing in both clinical trials within four to six months subject to any necessary regulatory approvals. The FDA has agreed to respond within 30 days upon Lpath’s request to reinstate dosing.
Scott Pancoast, Lpath’s president and chief executive officer, commented: "While we are disappointed to learn about these FDA concerns, we believe this issue does not affect the prospects for value creation by our PEDigree and Nexus studies."
"We continue to expect that the resolution of RPE detachments that we saw in each of the two patients in our Phase 1 trial will be repeated in our PEDigree study, and that the significant reductions in lesion size that we also saw in the Phase 1 trial will be repeated in the Nexus study," added Pancoast.
Conference Call
Lpath will hold a conference call tomorrow (Friday, January 27, 2012) at 8:45 a.m. Eastern time to discuss today’s news and the company’s outlook for 2012. President and CEO Scott Pancoast will host the call, with a question-and-answer session following management’s presentation.
Dial-in number: 1-877-941-2068 International dial-in: 1-480-629-9712 Conference ID number: 4510816
Internet simulcast and replay: http://viavid.net/dce.aspx?sid=00009327
Please call the conference telephone number 5-10 minutes prior to the start time. If you have any difficulty connecting with the conference call, please contact Liolios Group at 1-949-574-3860.
A telephone replay of the call will be available after 11:45 a.m. Eastern time and until February 27, 2012.
Toll-free replay number: 1-877-870-5176 International replay number: 1-858-384-5517 Replay pin number: 4510816
About Lpath San Diego-based Lpath, a therapeutic antibody company, is the category leader in lipidomics-based antibody therapeutics, an emerging field of medicine that targets bioactive signaling lipids for treating a wide range of human disease. Lpath’s ImmuneY2(TM) drug-discovery engine has the unique ability to generate therapeutic antibodies that bind to and inhibit bioactive lipids that contribute to disease. The company has developed three drug candidates, one of which (iSONEP(TM) for wet AMD) has initiated mid-stage clinical trials and another of which (ASONEP(TM) for cancer) will soon begin mid-stage clinical trials. The third candidate is a pre-clinical anti-LPA antibody, which has shown efficacy in animal models of pain, fibrosis, and traumatic brain injury. Lpath entered into an agreement with Pfizer (NYSE: PFE) in 2010 that provides Pfizer an exclusive option for a worldwide license to develop and commercialize iSONEP. For more information, visit www.Lpath.com.
SOURCE: Lpath
Post Views: 46
Management to Host Investor Conference Call Tomorrow, Friday, January 27 at 8:45 a.m. ET
SAN DIEGO, CA, USA I January 26, 2012 I Lpath, Inc. (OTCBB: LPTN), the industry leader in lipidomics-based antibody therapeutics, has temporarily suspended dosing patients in its PEDigree and Nexus trials. In these trials, iSONEP(TM) is being tested as a treatment for wet AMD (Nexus) and a related complication called Pigmented Epithelial Detachment (PEDigree).
The company has taken this action because it learned from the FDA that the company’s fill/finish contractor, Formatech, Inc., was not in compliance with FDA’s current Good Manufacturing Practice (cGMP) requirements during the period that the iSONEP clinical vials were filled. Accordingly, even though Lpath believes it has taken appropriate steps to oversee Formatech’s manufacturing in order to ensure product quality, it has suspended dosing as a precaution to ensure the continued safety of all patients in its clinical trials.
iSONEP was well tolerated by all patients in the Phase 1 trial and by all patients thus far in the PEDigree and Nexus trials. The company has received no claims raising safety concerns regarding iSONEP.
Lpath has initiated the process to manufacture additional drug substance and has identified an alternate fill/finish contractor. Lpath plans to resume dosing in both clinical trials within four to six months subject to any necessary regulatory approvals. The FDA has agreed to respond within 30 days upon Lpath’s request to reinstate dosing.
Scott Pancoast, Lpath’s president and chief executive officer, commented: "While we are disappointed to learn about these FDA concerns, we believe this issue does not affect the prospects for value creation by our PEDigree and Nexus studies."
"We continue to expect that the resolution of RPE detachments that we saw in each of the two patients in our Phase 1 trial will be repeated in our PEDigree study, and that the significant reductions in lesion size that we also saw in the Phase 1 trial will be repeated in the Nexus study," added Pancoast.
Conference Call
Lpath will hold a conference call tomorrow (Friday, January 27, 2012) at 8:45 a.m. Eastern time to discuss today’s news and the company’s outlook for 2012. President and CEO Scott Pancoast will host the call, with a question-and-answer session following management’s presentation.
Dial-in number: 1-877-941-2068 International dial-in: 1-480-629-9712 Conference ID number: 4510816
Internet simulcast and replay: http://viavid.net/dce.aspx?sid=00009327
Please call the conference telephone number 5-10 minutes prior to the start time. If you have any difficulty connecting with the conference call, please contact Liolios Group at 1-949-574-3860.
A telephone replay of the call will be available after 11:45 a.m. Eastern time and until February 27, 2012.
Toll-free replay number: 1-877-870-5176 International replay number: 1-858-384-5517 Replay pin number: 4510816
About Lpath San Diego-based Lpath, a therapeutic antibody company, is the category leader in lipidomics-based antibody therapeutics, an emerging field of medicine that targets bioactive signaling lipids for treating a wide range of human disease. Lpath’s ImmuneY2(TM) drug-discovery engine has the unique ability to generate therapeutic antibodies that bind to and inhibit bioactive lipids that contribute to disease. The company has developed three drug candidates, one of which (iSONEP(TM) for wet AMD) has initiated mid-stage clinical trials and another of which (ASONEP(TM) for cancer) will soon begin mid-stage clinical trials. The third candidate is a pre-clinical anti-LPA antibody, which has shown efficacy in animal models of pain, fibrosis, and traumatic brain injury. Lpath entered into an agreement with Pfizer (NYSE: PFE) in 2010 that provides Pfizer an exclusive option for a worldwide license to develop and commercialize iSONEP. For more information, visit www.Lpath.com.
SOURCE: Lpath
Post Views: 46
